Search Within

Eileen O'Reilly

Formats
  1. Meeting Abstract (364)
  2. Journal Article (358)
  3. Review (24)
  4. Book Section (9)
  5. Correspondence (9)
  6. Editorial (8)
  7. Conference Paper (5)
  8. Miscellaneous (5)
  9. Book Whole (4)
  10. Guidelines (3)
  11. Research Letter (1)
Groups
  1. Center for Pancreatic Cancer Research (790)
  2. Department of Medicine (790)
  3. Gastrointestinal Oncology Service (790)
  4. Solid Tumor Oncology Division (790)
  5. Epidemiology and Biostatistics (178)
  6. Surgery (168)

More Groups

People
  1. Ghassan Abou-Alfa (156)
  2. Kenneth Yu (121)
  3. David Kelsen (112)
  4. Maeve Lowery (99)
  5. Marinela Capanu (94)
  6. William Jarnagin (84)

More People

Years
  1. 2025 (38)
  2. 2024 (75)
  3. 2023 (73)
  4. 2022 (57)
  5. 2021 (54)
  6. 2020 (70)

More Years

Publications
  1. Journal of Clinical Oncology (294)
  2. Annals of Oncology (48)
  3. Cancer (27)
  4. Annals of Surgical Oncology (26)
  5. Clinical Cancer Research (23)
  6. Gastrointestinal Cancer Research (18)

More Publications

Publishers
  1. American Society of Clinical Oncology (308)
  2. Oxford University Press (71)
  3. Elsevier Inc. (49)
  4. Springer (47)
  5. Wiley Blackwell (42)
  6. American Association for Cancer Research (40)

More Publishers

Results (790)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Multiplatform molecular profiling of 2,400 pancreatic adenocarcinomas to identify targets for therapeutic intent
    Meeting Abstract

    Millis, S. Z.; Arguello, D.; Lowery, M. A.; O'Reilly, E. M.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Evaluation of PARP inhibition as a platinum sparing strategy in BRCA2-deficient pancreatic tumors
    Meeting Abstract

    Lowery, M. A.; Lee, A.; Tobias, E.; Sung, P.; Bhanot, U.; Shakya, R.; Ludwig, T.; O'Reilly, E. M.; Jasin, M.; Moynahan, M. E.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Treatment, outcomes, and clinical trial participation in very elderly patients (pts) with metastatic pancreas cancer (mPC)
    Meeting Abstract

    Li, D.; Capanu, M.; Yu, K. H.; Lowery, M. A.; Kelsen, D. P.; O'Reilly, E. M.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Multiplatform profiling of a fibrolamellar carcinoma cohort
    Meeting Abstract

    Harding, J. J.; Millis, S. Z.; O'Reilly, E. M.; Saltz, L.; Abou-Alfa, G. K.; Venook, A. P.; Mayer, R. J.; Choti, M. A.; Cosgrove, D.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Biomarker analysis in Phase 1b study of anti-cancer stem cell antibody Tarextumab (TAR) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) demonstrates pharmacodynamic (PD) modulation of the Notch pathway in patients (pts) with untreated metastatic pancreatic cancer (mPC)
    Meeting Abstract

    Kapoun, A.; O'reilly, E.; Cohn, A.; Bendell, J. C.; Smith, L.; Strickler, J. H.; Gluck, W.; Liu, Y. W.; Wallace, B.; Tam, R.; more...
    European Journal of Cancer (2014)

    Fulltext@MSK | Save
  • APACT: A phase III trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone as adjuvant therapy for patients with resected pancreatic cancer (PC)
    Meeting Abstract

    Tempero, M.; Cardin, D.; Biankin, A.; Goldstein, D.; Moore, M.; O'reilly, E.; Philip, P.; Riess, H.; Macarulla, T.; Yung, L.; more...
    American Journal of Gastroenterology (2014)

    Fulltext@MSK | Save
  • APACT: A phase III trial of nab-Paclitaxel (nab-P) plus Gemcitabine (Gem) vs Gem alone as adjuvant therapy for patients (pts) with resected pancreatic cancer (PC)
    Meeting Abstract

    Tempero, M. A.; Cardin, D.; Biankin, A.; Goldstein, D.; Moore, M.; O'Reilly, E. M.; Philip, P.; Riess, H.; Macarulla, T.; Yung, L.; more...
    Pancreas (2014)

    Fulltext@MSK | Save
  • DNA mismatch repair abnormalities in Acinar cell carcinoma of the pancreas: Frequency and clinical significance
    Journal Article

    Liu, W. G.; Shia, J. R.; Gonen, M.; Lowery, M. A.; O'Reilly, E. M.; Klimstra, D. S.
    Pancreas (2014)

    Fulltext@MSK | Save
  • Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer
    Journal Article

    Yu, K. H.; Ricigliano, M.; Hidalgo, M.; Abou-Alfa, G. K.; Lowery, M. A.; Saltz, L. B.; Crotty, J. F.; Gary, K.; Cooper, B.; Lapidus, R.; more...
    Clinical Cancer Research (2014)

    Fulltext@MSK | Save
  • A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression
    Journal Article

    Li, D.; Pant, S.; Ryan, D. P.; Laheru, D.; Bahary, N.; Dragovich, T.; Hosein, P. J.; Rolfe, L.; Saif, M. W.; Lavalle, J.; more...
    Pancreatology (2014)

    Fulltext@MSK | Save